Table 1.
Number of cases and demographic data.
| Phenotype | n (% women) | Mean age (SD) |
|---|---|---|
| PRS phenotypes | ||
| SCZ | 600 (35.7) | 61.31 (16.77) |
| BPD | 772 (63.3) | 69.88 (18.67) |
| Smoking | ||
| FTND | 4609 (52.5) | 57.26 (12.07) |
| FTND wo. adm. | 2940 (63.5) | 57.21 (11.16) |
| CPD | 35 754 (61.8) | 65.75 (16.82) |
| CPD wo. adm. | 31 511 (64.8) | 66.38 (16.96) |
| Ever‐smoking versus never‐smokinga | 35 567 (61.6) | 65.79 (16.83) |
| Ever‐smoking versus never‐smoking wo. adm.a | 31 330 (64.6) | 66.42 (16.97) |
| Substance use disorders | ||
| Alcohol use disorder | 8701 (32.7) | 55.74 (15.45) |
| Amphetamine use disorder | 1744 (33.5) | 41.17 (11.52) |
| Cocaine use disorder | 645 (28.5) | 38.84 (10.25) |
| Cannabis use disorder | 1896 (29.7) | 40.34 (11.76) |
| Opioid use disorder | 501 (49.1) | 51.13 (13.12) |
| Sedative use disorder | 1625 (51.8) | 54.91 (14.89) |
| EO | 2810 (34.7) | 39.56 (10.13) |
| Number of admissions | 10 036 (32.5) | 56.87 (16.47) |
| Total sample | 144 609 (53.7) | 56.60 (20.90) |
BPD, bipolar disorder; CPD, cigarettes per day; EO, early onset of alcohol and/or substance use disorder; FTND, Fagerström Test of nicotine dependence; PRS, polygenic risk scores; SCZ, schizophrenia; wo. adm., without admission to the addiction treatment program.
a
For ever‐smoking versus never‐smoking, the number of ever‐smokers is listed, and the control group consisted of 17 145 never smokers.